REG - Oddo BHF AIF PLC Mural Oncology PLC - Form 8.3 - Mural Oncology plc
Oddo BHF AIF PLC has made a disclosure under Rule 8.3 of the Irish Takeover Panel Act, 1997, regarding its interests in Mural Oncology PLC. The disclosure includes details of relevant securities owned, cash-settled derivatives, and stock-settled derivatives. Oddo BHF AIF PLC owns 603,000 securities, representing 3.48% of Mural Oncology PLC. No supplemental Form 8.3 is attached.
RNS Number : 2745J Oddo BHF AIF PLC 27 November 2025
Ap27
FORM 8.3
IRISH TAKEOVER PANEL
OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
(a) Full name of discloser | Oddo BHF AIF PLC |
(b) Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. | |
(c) Name of offeror/offeree in relation to whose relevant securities this form relates Use a separate form for each offeror/offeree | MURAL ONCOLOGY PLC |
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1) | |
(e) Date position held/dealing undertaken For an opening position disclosure, state the latest practicable date prior to the disclosure | 26/11/2025 |
(f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state "N/A" | N/A |
2. INTERESTS AND SHORT POSITIONS
If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.
Ap28
Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
(Note 2)
Class of relevant security (Note 3) | USD 0.01 | |||
Interests | Short positions | |||
Number | % | Number | % | |
(1) Relevant securities owned and/or controlled | 603 000 | 3.48% | ||
(2) Cash-settled derivatives | ||||
(3) Stock-settled derivatives (including options) and agreements to purchase/ sell | ||||
Total | 603 000 | 3.48% |
All interests and all short positions should be disclosed.
Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant security | USD 0.01 |
Purchase/sale | Purchase |
Number of securities | 603 000 |
Price per unit (Note 5) | USD 2.02 |
Ap29
(b) Cash-settled derivative transactions
- Class of relevant security
- Product description e.g. CFD
- Nature of dealing e.g. opening/ closing a long/ short position, increasing/ reducing a long/ short position
- Number of reference securities (Note 6)
- Price per unit (Note 5)
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
- Class of relevant security
- Product description e.g. call option
- Writing, purchasing, selling, varying etc.
- Number of securities to which option relates (Note 6)
- Exerciseprice per unit
- Type e.g. American, Europeanetc.
- Expiry date
- Option moneypaid/ received per unit
(ii) Exercise
- Class of relevant security
- Product description e.g. call option
- Exercising/ exercised against
- Number of securities
- Exercise price per unit (Note 5)
(d) Other dealings (including transactions in respect of new securities) (Note 3)
- Class of relevant security
- Nature of dealing e.g. subscription, conversion, exercise
- Details
- Price per unit (if applicable) (Note 5)
Ap30
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer.
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"
(b) Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
(c) Attachments
- Is a Supplemental Form 8 attached?
- NO
Date of disclosure | 27/11/2025 |
Contact name | Névine ZEMMOURI |
Telephone number | +33 1 44 51 85 22 controleaif@oddo-bhf.com |
Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END ITPKDLBLEFLXFBK
